Elise C. Kohn

Drug development and registration: Challenges and opportunities in ovarian cancer

E. Kohn, S. Ivy, S. P. Ivy, 2017, Cancer.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.

E. Kohn, Su-Chun Cheng, G. Shapiro, 2020, The Lancet. Oncology.